DiMauro, K. A., Heber, M. E., Lee, J., Cohen, J. A., Flanagan, E. P., Riley, C., Goldman, M. D., Zamvil, S. S., & Kunchok, A. C. (2025). Progressive Myelitis in a 63-Year-Old Woman. Neurology Neuroimmunology & Neuroinflammation, 12(2). https://doi.org/10.1212/nxi.0000000000200382

Siemers, E., Feaster, T., Sethuraman, G., Sundell, K., Skljarevski, V., Cline, E. N., Zhang, H., Jerecic, J., Honig, L. S., Salloway, S., Sperling, R., Trame, M. N., Dodds, M. G., & Johnson, K. (2025). INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The Journal of Prevention of Alzheimer’s Disease, 12(1), 100005. https://doi.org/10.1016/j.tjpad.2024.100005

Henick, B. S., Koch, P. D., Gainor, J. F., Awad, M. M., Chiuzan, C., Izard, S., Georgis, Y., Mallick, S., Garofano, R. F., Wong, C. V., Saqi, A., Grindheim, J., Schulze, K., Sonett, J. R., Rizvi, N. A., Izar, B., Taylor, A. M., & Shu, C. A. (2024). Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings. Journal for ImmunoTherapy of Cancer, 12(12), e009301. https://doi.org/10.1136/jitc-2024-009301

Moise, K. J., Ling, L. E., Oepkes, D., Tiblad, E., Verweij, E. J. T. J., Lopriore, E., Smoleniec, J., Sachs, U. J., Bein, G., Kilby, M. D., Miller, R. S., Devlieger, R., Audibert, F., Emery, S. P., Markham, K., Norton, M. E., Ocón-Hernández, O., Pandya, P., Pereira, L., … Bussel, J. B. (2024). Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn. New England Journal of Medicine, 391(6), 526–537. https://doi.org/10.1056/nejmoa2314466

Zisa, D., Zhang-Sun, J., Christos, P. J., & Kirou, K. A. (2024). Sustained depression of B cell counts in lupus nephritis after treatment with rituximab and/or belimumab is associated with fewer disease flares. Lupus, 33(9), 938–947. https://doi.org/10.1177/09612033241260283

Lamichhane, N., Melas, N., Bergqvist, V., Ekholm, N.-P., Olén, O., Ludvigsson, J. F., Hjortswang, H., Marsal, J., Eriksson, C., & Halfvarson, J. (2024). Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease. Digestive Diseases and Sciences, 69(6), 2175–2183. https://doi.org/10.1007/s10620-024-08422-9

Hilton, J. F., Ott, P. A., Hansen, A. R., Li, Z., Mathew, M., Messina, C. H., Dave, V., Ji, X., Karpinich, N. O., Hirschfeld, S., Ballas, M., & Zandberg, D. P. (2024). INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors. Cancer Immunology, Immunotherapy, 73(3). https://doi.org/10.1007/s00262-023-03623-z

Dioun, S., Chen, L., De Meritens, A. B., St. Clair, C. M., Hou, J. Y., Khoury-Collado, F., Pua, T., Hershman, D. L., & Wright, J. D. (2024). Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy. Gynecologic Oncology, 182, 70–74. https://doi.org/10.1016/j.ygyno.2023.12.027

Diaz-Cabrera, N. M., Bauman, B. M., Iro, M. A., Dabbah-Krancher, G., Molho-Pessach, V., Zlotogorski, A., Shamriz, O., Dinur-Schejter, Y., Sharon, T. D., Stepensky, P., Tal, Y., Eisenstein, E. M., Pietzsch, L., Schuetz, C., Abreu, D., Coughlin, C. C., Cooper, M. A., Milner, J. D., Williams, A., … Leiding, J. W. (2024). Management of Atopy with Dupilumab and Omalizumab in CADINS Disease. Journal of Clinical Immunology, 44(2). https://doi.org/10.1007/s10875-023-01636-y

Askanase, A., Khalili, L., Tang, W., Mertz, P., Scherlinger, M., Sebbag, E., Chasset, F., Felten, R., & Arnaud, L. (2023). New and future therapies: Changes in the therapeutic armamentarium for SLE. Best Practice & Research Clinical Rheumatology, 37(4), 101865. https://doi.org/10.1016/j.berh.2023.101865

Elez, E., Kopetz, S., Tabernero, J., Bekaii-Saab, T., Taieb, J., Yoshino, T., Manji, G., Fernandez, K., Abbattista, A., Zhang, X., & Morris, V. K. (2024). SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAF V600E-mutant mCRC. Future Oncology, 20(11), 653–663. https://doi.org/10.2217/fon-2022-1249

Chen, A. P., Sharon, E., O’Sullivan-Coyne, G., Moore, N., Foster, J. C., Hu, J. S., Van Tine, B. A., Conley, A. P., Read, W. L., Riedel, R. F., Burgess, M. A., Glod, J., Davis, E. J., Merriam, P., Naqash, A. R., Fino, K. K., Miller, B. L., Wilsker, D. F., Begum, A., … Doroshow, J. H. (2023). Atezolizumab for Advanced Alveolar Soft Part Sarcoma. New England Journal of Medicine, 389(10), 911–921. https://doi.org/10.1056/nejmoa2303383

Ostrowitzki, S., Bittner, T., Sink, K. M., Mackey, H., Rabe, C., Honig, L. S., Cassetta, E., Woodward, M., Boada, M., van Dyck, C. H., Grimmer, T., Selkoe, D. J., Schneider, A., Blondeau, K., Hu, N., Quartino, A., Clayton, D., Dolton, M., Dang, Y., … Doody, R. S. (2022). Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease. JAMA Neurology, 79(11), 1113. https://doi.org/10.1001/jamaneurol.2022.2909

Lonze, B. E., Spiegler, P., Wesson, R. N., Alachkar, N., Petkova, E., Weldon, E. P., Dieter, R. A., Li, Y., Quinn, M., Mattoo, A., Soomro, I., Cohen, S. M., Leung, S., Deterville, C. L., Landrum, B. M., Ali, M. I., Cohen, D. J., Singer, A. L., Sen, A., … Montgomery, R. A. (2022). A Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab for the Treatment of COVID-19 Pneumonia With Hyperinflammation*. Critical Care Medicine, 50(9), 1348–1359. https://doi.org/10.1097/ccm.0000000000005591

Albuquerque, A. M., Tramujas, L., Sewanan, L. R., Williams, D. R., & Brophy, J. M. (2022). Mortality Rates Among Hospitalized Patients With COVID-19 Infection Treated With Tocilizumab and Corticosteroids. JAMA Network Open, 5(2), e220548. https://doi.org/10.1001/jamanetworkopen.2022.0548

Schöffski, P., Tan, D. S. W., Martín, M., Ochoa-de-Olza, M., Sarantopoulos, J., Carvajal, R. D., Kyi, C., Esaki, T., Prawira, A., Akerley, W., De Braud, F., Hui, R., Zhang, T., Soo, R. A., Maur, M., Weickhardt, A., Krauss, J., Deschler-Baier, B., Lau, A., … Hong, D. S. (2022). Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. Journal for ImmunoTherapy of Cancer, 10(2), e003776. https://doi.org/10.1136/jitc-2021-003776

Powles, T., Yuen, K. C., Gillessen, S., Kadel, E. E., Rathkopf, D., Matsubara, N., Drake, C. G., Fizazi, K., Piulats, J. M., Wysocki, P. J., Buchschacher, G. L., Alekseev, B., Mellado, B., Karaszewska, B., Doss, J. F., Rasuo, G., Datye, A., Mariathasan, S., Williams, P., & Sweeney, C. J. (2022). Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nature Medicine, 28(1), 144–153. https://doi.org/10.1038/s41591-021-01600-6